PetVivo Holdings, Inc. (PETV)
USD 0.63
(4.99%)
USD 0.63
(4.99%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -10.62 Million USD | -21.62% |
| 2023 | -8.73 Million USD | -72.72% |
| 2022 | -5.05 Million USD | -158.12% |
| 2021 | -1.95 Million USD | 2.83% |
| 2020 | -2.01 Million USD | 56.85% |
| 2019 | -4.67 Million USD | -104.47% |
| 2018 | -2.28 Million USD | 86.06% |
| 2017 | -16.38 Million USD | -404.11% |
| 2016 | -3.25 Million USD | -170.51% |
| 2015 | -1.2 Million USD | 96.75% |
| 2014 | -36.97 Million USD | -44769.16% |
| 2013 | -82.4 Thousand USD | 19.53% |
| 2012 | -102.4 Thousand USD | 61.03% |
| 2011 | -262.78 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 FY | -10.62 Million USD | -21.62% |
| 2024 Q1 | -2.89 Million USD | -24.24% |
| 2024 Q2 | -2.94 Million USD | -1.75% |
| 2024 Q4 | -2.64 Million USD | -24.19% |
| 2024 Q3 | -2.13 Million USD | 27.53% |
| 2023 Q4 | -2.32 Million USD | -0.44% |
| 2023 Q3 | -2.31 Million USD | -9.4% |
| 2023 Q2 | -2.11 Million USD | -7.81% |
| 2023 Q1 | -1.96 Million USD | -10.64% |
| 2023 FY | -8.73 Million USD | -72.72% |
| 2022 Q2 | -1.1 Million USD | -112.79% |
| 2022 FY | -5.05 Million USD | -158.12% |
| 2022 Q1 | -518.51 Thousand USD | -65.68% |
| 2022 Q3 | -1.65 Million USD | -50.24% |
| 2022 Q4 | -1.77 Million USD | -7.2% |
| 2021 Q2 | -818.56 Thousand USD | -85.17% |
| 2021 Q1 | -442.06 Thousand USD | 14.99% |
| 2021 FY | -1.95 Million USD | 2.83% |
| 2021 Q3 | -385.39 Thousand USD | 52.92% |
| 2021 Q4 | -312.96 Thousand USD | 18.79% |
| 2020 FY | -2.01 Million USD | 56.85% |
| 2020 Q1 | -493.72 Thousand USD | 61.68% |
| 2020 Q2 | -429.61 Thousand USD | 12.98% |
| 2020 Q3 | -572.76 Thousand USD | -33.32% |
| 2020 Q4 | -520.03 Thousand USD | 9.21% |
| 2019 Q1 | 2.09 Million USD | 319.36% |
| 2019 Q4 | -1.28 Million USD | -130.25% |
| 2019 Q3 | -559.61 Thousand USD | 23.09% |
| 2019 Q2 | -727.59 Thousand USD | -134.7% |
| 2019 FY | -4.67 Million USD | -104.47% |
| 2018 FY | -2.28 Million USD | 86.06% |
| 2018 Q4 | -956 Thousand USD | -79.4% |
| 2018 Q3 | -532.89 Thousand USD | -70.2% |
| 2018 Q1 | -483.32 Thousand USD | 28.52% |
| 2018 Q2 | -313.1 Thousand USD | 35.22% |
| 2017 FY | -16.38 Million USD | -404.11% |
| 2017 Q1 | -626.22 Thousand USD | 63.85% |
| 2017 Q4 | -676.18 Thousand USD | -35.63% |
| 2017 Q3 | -498.53 Thousand USD | 96.62% |
| 2017 Q2 | -14.74 Million USD | -2253.81% |
| 2016 Q1 | -1 Million USD | -495.05% |
| 2016 FY | -3.25 Million USD | -170.51% |
| 2016 Q4 | -1.73 Million USD | -438.7% |
| 2016 Q3 | -321.6 Thousand USD | -71.54% |
| 2016 Q2 | -187.47 Thousand USD | 81.43% |
| 2015 Q2 | -105.83 Thousand USD | 88.49% |
| 2015 Q1 | -919.52 Thousand USD | -13.36% |
| 2015 FY | -1.2 Million USD | 96.75% |
| 2015 Q3 | -200.81 Thousand USD | -89.74% |
| 2015 Q4 | -169.66 Thousand USD | 15.51% |
| 2014 Q4 | -811.15 Thousand USD | -954.75% |
| 2014 Q3 | 94.89 Thousand USD | 110.69% |
| 2014 Q2 | -887.76 Thousand USD | -4753.53% |
| 2014 FY | -36.97 Million USD | -44769.16% |
| 2014 Q1 | -18.29 Thousand USD | -19.09% |
| 2013 Q1 | -23.23 Thousand USD | 47.2% |
| 2013 Q2 | -22.72 Thousand USD | 2.18% |
| 2013 Q3 | -21.08 Thousand USD | 7.21% |
| 2013 Q4 | -15.35 Thousand USD | 27.16% |
| 2013 FY | -82.4 Thousand USD | 19.53% |
| 2012 Q3 | -23.65 Thousand USD | -70.68% |
| 2012 Q2 | -13.85 Thousand USD | 33.69% |
| 2012 Q1 | -20.89 Thousand USD | -50.28% |
| 2012 FY | -102.4 Thousand USD | 61.03% |
| 2012 Q4 | -44 Thousand USD | -86.03% |
| 2011 FY | -262.78 Thousand USD | 0.0% |
| 2011 Q1 | -170 Thousand USD | 0.0% |
| 2011 Q2 | -40.9 Thousand USD | 75.94% |
| 2011 Q3 | -35.85 Thousand USD | 12.34% |
| 2011 Q4 | -13.9 Thousand USD | 61.21% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Acutus Medical, Inc. | -14.36 Million USD | 26.04% |
| Biotricity, Inc. | -8.82 Million USD | -20.311% |
| Cell MedX Corp. | -313.43 Thousand USD | -3288.744% |
| Dynatronics Corporation | -2.27 Million USD | -367.273% |
| Nemaura Medical Inc. | -9.59 Million USD | -10.694% |
| RetinalGenix Technologies Inc. | -2.08 Million USD | -408.917% |
| Sonendo, Inc. | -57.74 Million USD | 81.606% |
| Telesis Bio, Inc. | -35.15 Million USD | 69.783% |
| Talis Biomedical Corporation | -66.81 Million USD | 84.103% |
| Viveve Medical, Inc. | -21.55 Million USD | 50.72% |